Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Finke

Showing results (121-130 of 180) with videos related to

Pageof 18
Sort By:
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
Blood Cancer Journal|November 21, 2018
Genetic predictors of response to specific drugs in primary myelofibrosisDomenico Penna, Natasha Szuber, Terra L Lasho, et al.
American Journal of Hematology|April 28, 2011
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patientsMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasmsAnimesh Pardanani, Terra L Lasho, Christy M Finke, et al.
Leukemia Research|September 28, 2023
TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemiaMark Gurney, Patricia T Greipp, Troy Gliem, et al.
American Journal of Hematology|January 22, 2013
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevanceMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Blood Cancer Journal|January 26, 2019
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapyNaseema Gangat, Amy Phelps, Terra L Lasho, et al.
Leukemia|April 6, 2013
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMMLR R Laborde, M M Patnaik, T L Lasho, et al.
Leukemia|May 2, 2018
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML aloneMrinal M Patnaik, Rangit Vallapureddy, Terra L Lasho, et al.
Haematologica|January 5, 2019
Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the <i>JAK2</i>V617F mutationMrinal M Patnaik, Prateek A Pophali, Terra L Lasho, et al.
Pageof 18

Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
Blood Cancer Journal|November 21, 2018
Genetic predictors of response to specific drugs in primary myelofibrosisDomenico Penna, Natasha Szuber, Terra L Lasho, et al.
American Journal of Hematology|April 28, 2011
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patientsMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasmsAnimesh Pardanani, Terra L Lasho, Christy M Finke, et al.
Leukemia Research|September 28, 2023
TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemiaMark Gurney, Patricia T Greipp, Troy Gliem, et al.
American Journal of Hematology|January 22, 2013
Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevanceMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Blood Cancer Journal|January 26, 2019
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapyNaseema Gangat, Amy Phelps, Terra L Lasho, et al.
Leukemia|April 6, 2013
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMMLR R Laborde, M M Patnaik, T L Lasho, et al.
Leukemia|May 2, 2018
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML aloneMrinal M Patnaik, Rangit Vallapureddy, Terra L Lasho, et al.
Haematologica|January 5, 2019
Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the <i>JAK2</i>V617F mutationMrinal M Patnaik, Prateek A Pophali, Terra L Lasho, et al.
Pageof 18